{
  "metadata": {
    "case_id": 94,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T19:35:01.102268",
    "total_alignments": 5,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/94_NCT03408730.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/94_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.identificationModule.secondaryIdInfos",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.95
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "id": "2017-001820-22",
            "type": "EUDRACT_NUMBER"
          },
          "pred_item": {
            "id": "2017-001820-22",
            "type": "EUDRACT_NUMBER",
            "domain": "EU Clinical Trials"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.82,
          0.72
        ],
        [
          0.74,
          0.65
        ],
        [
          0.7,
          0.6
        ],
        [
          0.3,
          0.75
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "label": "Sci-B-Vac Lot A Hep B Vaccination",
            "type": "EXPERIMENTAL",
            "description": "Sci-B-Vac Lot A Hepatitis B Vaccination",
            "interventionNames": [
              "Biological: Hepatitis B Vaccination"
            ]
          },
          "pred_item": {
            "label": "3A-HBV Groups",
            "type": "EXPERIMENTAL",
            "description": "Participants were randomized to 1 of 3 independent consecutive lots (A, B, and C) of 3A-HBV. They received a 1-mL dose of 3A-HBV (10 μg) by intramuscular injection on study days 0, 28, and 168.",
            "interventionNames": [
              "3A-HBV"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Sci-B-Vac Lot B Hep B Vaccination",
            "type": "EXPERIMENTAL",
            "description": "Sci-B-Vac Lot B Hepatitis B Vaccination",
            "interventionNames": [
              "Biological: Hepatitis B Vaccination"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Sci-B-Vac Lot C Hep B Vaccination",
            "type": "EXPERIMENTAL",
            "description": "Sci-B-Vac Lot C Hepatitis B Vaccination",
            "interventionNames": [
              "Biological: Hepatitis B Vaccination"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": 1,
          "score": 0.75,
          "status": "matched",
          "ref_item": {
            "label": "Comparator: ENGERIX-B Hep B Vaccination",
            "type": "ACTIVE_COMPARATOR",
            "description": "Active Comparator: ENGERIX-B Hepatitis B Vaccination",
            "interventionNames": [
              "Biological: Hepatitis B Vaccination"
            ]
          },
          "pred_item": {
            "label": "1A-HBV Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants were randomized to the control group receiving 1A-HBV. They received a 1-mL dose of 1A-HBV (20 μg) by intramuscular injection on study days 0, 28, and 168.",
            "interventionNames": [
              "1A-HBV"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.82,
          0.86
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "Hepatitis B Vaccination",
            "description": "Hepatitis B Vaccination",
            "armGroupLabels": [
              "Comparator: ENGERIX-B Hep B Vaccination",
              "Sci-B-Vac Lot A Hep B Vaccination",
              "Sci-B-Vac Lot B Hep B Vaccination",
              "Sci-B-Vac Lot C Hep B Vaccination"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "1A-HBV",
            "description": "A single-antigen (1A) HBV vaccine provided as 1-mL vials containing 20 μg of HBsAg-S adsorbed onto 0.5 mg of Al3+ as aluminum hydroxide adjuvant, sourced commercially.",
            "armGroupLabels": [
              "1A-HBV Group"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.97
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Geometric Mean Concentration (GMC) of Anti-HBs at Day 196 for Lot-to-Lot Consistency (Per Protocol Set 1)",
            "description": "To demonstrate the manufacturing equivalence, in terms of immunogenicity, as measured by GMC of antibodies, of 3 independent consecutive lots of the Sci-B-Vac® 4 weeks after the third vaccination. Lot-to-lot manufacturing consistency of Sci-B-Vac® is demonstrated if the 95% CIs of the adjusted anti-HBs GMC ratios between lots are within the pre-specified range of \\[0.67, 1.5\\].",
            "timeFrame": "4 weeks after third vaccination (Study Day 196)"
          },
          "pred_item": {
            "measure": "Geometric Mean Concentration (GMC) of Anti-HBs (Manufacturing Equivalence)",
            "description": "Assessment of manufacturing equivalence (lot-to-lot consistency) of 3 independent consecutive 3A-HBV lots. Consistency was demonstrated if the upper and lower bound of the 2-sided 95% CI of the GMC of anti-HBs ratios for all 3 pairwise comparisons were between 0.67 and 1.50.",
            "timeFrame": "4 weeks after the third injection (Day 196)"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.93,
          0.15
        ],
        [
          0.1,
          0.86
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2)",
            "description": "The difference in proportions \\[SPR(Sci-B-Vac®)-SPR(Engerix-B®)\\] and two-sided 95% CIs were summarized. If the lower bound of the 95% CI was \\> 5%, Sci-B-Vac® was to be declared non-inferior to Engerix-B®",
            "timeFrame": "4 weeks after third vaccination (Study Day 196)"
          },
          "pred_item": {
            "measure": "Seroprotection Rate (SPR) Noninferiority",
            "description": "The proportion of participants achieving seroprotection, defined as a hepatitis B surface antibody (anti-HBs) concentration of at least 10 mIU/mL. Noninferiority is demonstrated if the lower bound of the 2-sided 95% CI of the difference between the SPR for 3A-HBV and 1A-HBV is greater than -5%.",
            "timeFrame": "4 weeks after the third injection (Day 196)"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs)",
            "description": "Analysis of local and systemic solicited adverse events with an interval of onset of Day 1 to Day 7 after any vaccination with either Sci-B-Vac® or Engerix-B®, in adults ≥18 years old.",
            "timeFrame": "Day of vaccine administration and six subsequent days"
          },
          "pred_item": {
            "measure": "Safety and Reactogenicity",
            "description": "Incidence of solicited local and systemic adverse events (AEs), unsolicited AEs, and serious adverse events (SAEs).",
            "timeFrame": "Solicited AEs within 7 days of vaccination; Unsolicited AEs within 28 days of vaccination; SAEs throughout study period (Day 1 to Day 336)"
          }
        }
      ]
    }
  ]
}